Background: Several studies have reported an association between the A23G polymorphism (rs 1800975) in the xeroderma pigmentosum group A (XPA) gene and risk of digestive system cancers. However, the results are inconsistent. In this study, we performed a meta-analysis to assess the association between XPA A23G polymorphism and the risk of digestive system cancers. Methods: Relevant studies were identified using the PubMed, Web of Science, China National Knowledge Infrastructure, WanFang, and VIP databases up to August 30, 2014. The pooled odds ratio (OR) with a 95% confidence interval (CI) was calculated using the fixed or random effects model. Results: A total of 18 case-control studies from 16 publications with 4,170 patients and 6,929 controls were included. Overall, no significant association was found between XPA A23G polymorphism and the risk of digestive system cancers (dominant model: GA + AA versus GG, OR 0.89, 95% CI 0.74-1.08; recessive model: AA versus GA + GG, OR 0.94, 95% CI 0.74-1.20; GA versus GG, OR 0.89, 95% CI 0.77-1.03; and AA versus GG, OR 0.87, 95% CI 0.64-1.19). When the analysis was stratified by ethnicity, similar results were observed among Asians and Caucasians in all genetic models. In stratified analysis based on tumor type, we also failed to detect any association between XPA A23G polymorphism and the risk of esophageal, gastric, or colorectal cancers.
Introduction
Gastrointestinal cancers, referring to a group of malignancies affecting the esophagus, stomach, liver, bowel, pancreas, gallbladder, and anus, are the most common cancers worldwide. 1 There are an estimated 3.4 million new cases worldwide each year, and their mortality rates have increased gradually over the past decade. 1 The exact mechanism of carcinogenesis is still not fully understood. It is well established that some risk factors (eg, dietary, racial, and socioeconomic) and interactions between genetic and environmental factors play important roles in the pathogenesis of cancer.
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he at al in nucleotide excision repair (NER) through its interaction with replication protein A, transcription factor II H, and the excision repair cross-complementing group 1-xeroderma pigmentosum group F protein complex. 5, 6 In addition, XPA is involved in both global genome and transcription-coupled repair pathways, 7 and interacts with many core repair factors during the DNA repair process. 8 In the XPA gene, a polymorphic site has been identified in the 5′ untranslated region and consists of an A to G substitution in the fourth nucleotide before the ATG start codon (XPA A23G, rs 1800975). It has been shown that the polymorphism could affect protein levels in the cell. 9, 10 To date, a large number of molecular epidemiologic studies have been conducted to assess the role of A23G polymorphism in XPA gene on various types of cancers, especially those affecting the digestive system. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] However, the results have been inconclusive or inconsistent. Individual studies might have been underpowered to detect the effect of this polymorphism on susceptibility to cancer. Therefore, we conducted a meta-analysis to evaluate the association between XPA A23G polymorphism and the susceptibility to digestive system cancers.
Methods search strategy
We searched the electronic literature in the PubMed, Web of Science, China National Knowledge Infrastructure, WanFang, and VIP databases for all relevant articles. The last search update was August 30, 2014 , using the search terms: "xeroderma pigmentosum group A or XPA or DNA repair gene or NER", "genetic polymorphism or polymorphisms or variant", and "digestive system cancer or gastrointestinal cancers or gastric cancer or colorectal cancer or hepatocellular carcinoma or esophageal cancer or pancreatic cancer". The search was restricted to humans without language restrictions. Additional studies were identified by a hand search of references of original or review articles on this topic. If more than one geographic or cancer type was reported in one report, each was extracted separately. If data or data subsets were published in more than one article, only the publication with the largest sample size was included.
inclusion and exclusion criteria
Studies included in this meta-analysis had to meet the following criteria: studies that evaluated the association between XPA A23G polymorphism and digestive system cancers, in a case-control study design, and had detailed genotype frequency of cases and controls or could be calculated from the article text. We excluded case-only studies, case reports, review articles, studies without raw data for the XPA A23G genotype, and repetitive publications.
Data extraction
For each study, the following data were extracted independently by two investigators: the first author's name, year of publication, country of origin, ethnicity, age, sex, source of controls, genotype methods, number of cases and controls (total and genotypes), and Hardy-Weinberg equilibrium (HWE) in controls (P-value). The results were compared, and disagreements were discussed among all authors and resolved with consensus. Different eth nicity was categorized as Asian and Caucasian.
Quality assessment
The quality of the eligible studies was assessed using Newcastle-Ottawa Scale (NOS), which is widely used for assessment of the quality of observational studies, including cohort or case-control studies. 31 NOS, consisting of three parts (selection, comparability, and exposure), is a star-rewarded scale. A total of four, two, and three stars, respectively, will be rewarded if the criteria are met. A study with seven or more stars was categorized as high quality, otherwise, the study was categorized as low quality.
statistical analysis
HWE was evaluated for each study using an Internet-based HWE calculator (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). The risk of digestive system cancers associated with XPA A23G polymorphism was estimated for each study by odds ratio (OR) and 95% confidence interval (CI). The most common G allele was considered the reference genotype and the rare A allele was examined as the variant in this analysis. Four different ORs were calculated: the dominant model (AG + AA versus GG), the recessive model (AA versus AG + GG), heterozygote comparison (AG versus GG), and homozygote comparison (AA versus GG). A χ 2 -test-based Q statistic test was performed to assess between-study heterogeneity. 32 We also quantified the effect of heterogeneity by I 2 test. When a significant Q test (P0.1) or I 2 50% indicated homogeneity across studies, the fixed effects model was used, 33 or else the random effects model was used. 34 We then performed stratification analyses on ethnicity, tumor type, and source of control. Analysis of sensitivity was performed to evaluate the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the individual data set on the pooled OR. Finally, potential publication bias was investigated using Begg's funnel plot 
Results
study characteristics
After an initial search, a total of 101 published articles relevant to the topic were identified. According to the inclusion criteria, 20 studies [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] with full text were included in this meta-analysis and 81 studies were excluded. The flow chart for study selection is summarized in Figure 1 . Because the study by Huang et al 17 included two types of cancer, we treated them separately in this meta-analysis; three articles [27] [28] [29] that had overlapped study data were also excluded. Moreover, we excluded one study 30 because it did not present detailed genotyping information. Therefore, as shown in Table 1 , there were 18 case-control studies [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] with 4,170 cases and 6,929 controls concerning XPA A23G polymorphism. Of the 18 eligible studies, nine studies 12, 14, 15, 17, 20, 22, [24] [25] [26] involved esophageal cancers, four studies 11, 17, 21 involved gastric cancers, four 13, 16, 18, 19 involved colorectal cancers, and one 23 involved hepatocellular carcinoma. Two ethnicities were addressed: eleven studies 11, 12, 14, 17, 20, [23] [24] [25] [26] were conducted in Asian populations and seven studies 13, 15, 16, 18, 19, 21, 22 in Caucasian populations. The distribution of genotypes in the controls was consistent with HWE for all selected studies. The quality of all eligible studies was categorized as high except for one study. 20 
Quantitative data synthesis
As shown in Table 2 , overall no significant association was found between XPA A23G polymorphism and the risk of digestive system cancers (dominant model: OR 0.89, 95% CI 0.74-1.08; recessive model: OR 0.94, 95% CI 0.74-1.20; GA versus GG, OR 0.89, 95% CI 0.77-1.03; and AA versus GG, OR 0.87, 95% CI 0.64-1.19, Figure 2 ).
In subgroup analysis by ethnicity, there was no significant association between XPA A23G polymorphism and the risk of digestive system cancers in either Asians or Caucasians (Table 2, Figure 3 ).
In stratified analysis based on tumor type, we also failed to detect any association between XPA A23G polymorphism and the risk of esophageal, gastric, or colorectal cancers. In addition, only one study focused on hepatocellular carcinoma, and the results showed no association between XPA A23G polymorphism and the risk of hepatocellular carcinoma (Table 2, Figure 4 ).
When the analysis was stratified by source of control, we found that XPA A23G polymorphism was associated with a decreased risk of digestive system cancers in populationbased models (GA versus GG, OR 0.86, 95% CI 0.77-0.96), but not in other genetic models or hospital-based populations (Table 2) . However, it is worth noting that there was moderate heterogeneity (I 2 =40%) in the subgroup analysis; when the study by Zhen et al was excluded, the heterogeneity disappeared (I 2 =0%), and the pooled results showed no significant differences in genotype distribution between digestive system cancer cases and controls (OR 0.92, 95% CI 0.82-1.04). Therefore, the results that included the study by Zhen et al should be cautiously interpreted.
heterogeneity and sensitivity analyses
Substantial heterogeneity was observed between studies for the association between XPA A23G polymorphism and digestive system cancer risk in all genetic models (dominant 2 =83%, P0.00001). We therefore assessed the source of heterogeneity by ethnicity, tumor type, and source of control. The heterogeneity was partly decreased or removed for gastric cancers, colorectal cancers, Caucasians, and population-based studies. However, there was still significant heterogeneity for esophageal cancer, Asians, and hospital-based populations. Sensitivity analysis was then performed to evaluate the stability of the results. The statistical significance of the results was not altered when any single study was omitted, confirming the stability of the findings.
Publication bias
We used the Begg's funnel plot and Egger's test to address potential publication bias in the available literature. The shape of the funnel plots did not reveal any evidence of funnel plot asymmetry ( Figure 5 
Discussion
The evidence suggests that reduced DNA repair capacity may lead to genetic instability and carcinogenesis, genes involved in DNA repair have been proposed as candidate cancer susceptibility genes. 37 The NER pathway may be important in modulating susceptibility to cancer, because it is the primary mechanism for repair of a wide variety of types of DNA damage. [38] [39] [40] There are several core genes in the NER pathway (eg, ERCC1, XPA, XPB/ERCC3, XPC, XPD/ERCC2, XPE/DDB1, XPF/ERCC4, and XPG/ERCC5). Of these, the XPA gene is one of the central players, with a vital role in repairing DNA damage and maintaining the integrity of the genome. 4 Recently, A23G polymorphism of the XPA gene was reported to confer a risk of digestive system cancers. Furthermore, a number of epidemiological studies have evaluated the association between this polymorphism and risk of digestive system cancers, but the results remain inconclusive. Dong et al 11 and Guo et al 14 reported that the XPA A23G polymorphism was associated with a decreased risk of esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a high-incidence population in northern China; however, in a study from the USA, Pan et al 22 suggested that the heterozygous AG genotype of the XPA 5′ untranslated region was associated with a 2.11-fold increased risk, and the increased risk reached 3.10-fold Gil et al 13 Hall et al 15 Hansen et al 16 Jelonek et al 18 Joshi et al 19 Palli et al 21 Pan 12 Gil et al 13 Guo et al 14 Hall et al 15 Hansen et al 16 Huang et al 17 Huang et al 17 Huang et al 17 Jelonek et al 18 Joshi et al 19 Liu 20 Palli et al 21 Pan for the homozygous variant GG genotype in esophageal cancer. Furthermore, Gil et al 13 found that the XPA A23G polymorphism may be unrelated to the risk of sporadic colorectal cancer; similarly, Hansen et al 16 failed to detect an association between the polymorphism and risk of colorectal cancer in a Danish population. These inconsistent results may be attributed to differences in genetic backgrounds, environmental factors, and other factors.
A recent meta-analysis 41 evaluated the association between XPA A23G polymorphism and cancer risk, and reported that this polymorphism is associated with an increased lung cancer risk and may be a low-penetrant risk factor for development of cancer in people of Asian ethnicity. Subsequently, Liu et al 42 conducted another meta-analysis to assess the association between A23G polymorphism and risk of cancer, and suggested that the XPA A23G G allele is a low-penetrant risk factor for development of cancer. However, only few studies focusing on digestive system cancers (eight and nine studies, respectively) were included in the above meta-analysis, and due to the limited study number, further analyses was not conducted. Compared with those stud- 
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he at al publication bias in this meta-analysis, suggesting that our results are reliable. With regard to heterogeneity, in this metaanalysis, heterogeneity was found in overall comparison under all genetic models, when stratified by ethnicity, tumor type, and source of control, the heterogeneity was partly decreased or removed among gastric and colorectal cancers, Caucasians, and population-based subgroups. However, heterogeneity still existed for esophageal cancer, Asians, and hospital-based populations. In addition, when the study by Zhen et al was excluded, the heterogeneity decreased. Our results suggest that the ethnic background, different types of tumor, and the particular study might be the source of heterogeneity. Then sensitivity analyses were conducted by successively excluding one study, the estimated pooled odd ratio changed quite little, indicating that the results of this meta-analysis were stable.
This meta-analysis has limitations that must be acknowledged. First, all case-control studies included were done in Asians and Caucasians, so our results may be applicable only to these populations. More studies on Africans and other ethnic groups are needed. Second, the controls included in our analysis were selected variously from either population-based or hospitals. Therefore, misclassification bias was possible because these studies may have included control groups that have different risks for developing digestive system cancers. Third, our results were based on unadjusted estimates, without adjustment for family history or other risk factors, which may cause serious confounding bias.
Conclusion
In summary, this meta-analysis suggests that XPA A23G polymorphism is not associated with a risk of digestive ies, we conducted a more comprehensive literature search in different databases (including Web of Science, China National Knowledge Infrastructure, WanFang, and VIP) and included several additional studies, 17, 19, 20, [23] [24] [25] [26] which allowed for a larger number of subjects and more precise risk estimation. In this meta-analysis, we pooled 18 studies to explore the association between A23G polymorphism and risk of gastrointestinal cancers. The results demonstrated that XPA A23G polymorphism is not associated with digestive system cancer risk.
The outcomes from meta-analysis can be affected by several factors, such as ethnicity, cancer origin, and control selection. Therefore, subgroup analyses were conducted. In this study, stratification by ethnicity, tumor type, and source of control revealed no significant association. The results seem to contradict the previous meta-analyses. The discrepancies are probably due to the small size of the A23G polymorphism in determining susceptibility to digestive system cancers in the previous meta-analyses. Moreover, the biological mechanisms of the XPA gene in carcinogenesis are complicated, and may be mediated by the activities of multiple genes (such as ERCC1 and XPF) in the NER pathway, the function of which may be different in digestive system cancers than in other cancers. In addition, cancer is a multifactorial disease that results from complex interactions between many environmental and genetic factors. Therefore, when we only consider suspected gene polymorphism in digestive system cancers and ignore the role of other genes and environmental factors, we might fail to conclude a real association.
Two significant issues should be addressed in this study, ie, heterogeneity and publication bias, which may influence the results of a meta-analysis. We did not detect a significant 
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XPa a23g polymorphism and digestive system cancers system cancers. However, large and well-designed studies taking into consideration gene-gene and gene-environment interactions are warranted to validate our findings.
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